Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Slides:

Advertisements

Similar presentations

PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected patients receiving CZP from Week.

Advertisements

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from baseline to 12 months follow-up in patients.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Resolution of tophi after exposure to pegloticase.

MTX-PG concentrations and hepatotoxicity.

ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.

Box plot showing median cytokine levels and IQRs for (A) IP-10, (B) TNF-α, (C) LT-α and (D) IFN-γ in controls and pSS fatigue groups. Box plot showing.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Independent baseline predictors of non-remission at 24 months of follow-up in the SWEFOT trial population. Independent baseline predictors of non-remission.

Effect of CIA and treatment with 3,4-dichloropropionaniline (DCPA) on production of key serum inflammatory factors. Effect of CIA and treatment with 3,4-dichloropropionaniline.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.

Changes in clinical outcome measures over 24 months on a continuous scale in the whole SWEFOT trial population with available baseline BMI categories.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

Radiographic endpoints: (A) change from baseline in SHS at Week 52 and Week 104*†; (B) probability plots of change from baseline in SHS at Week 52 and.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Employment of patients with AS compared with controls, by BASDAI

DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

Follow-up and cause of anti-TNF-α discontinuation in 15 patients with rhupus. anti-TNF-α, antitumour necrosis factor alpha; ESR, erythrocyte sediment rate;

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Systematic review and network meta-analyses study selection flow chart

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

Multivariable model of adjusted

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

Presentation transcript:

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at multiple time-points. Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at multiple time-points. Proportion of patients with radiographic progression defined as (A) ΔSHS>5 and (B) ΔSHS>3. Left and middle bar graphs represent proportion of patients with 2-year radiographic progression stratified by the MBDA score at BL and month 3, respectively. Right bar graph shows radiographic progression from year 1 to 2 among patients stratified by the MBDA score at year 1. BL, baseline; MBDA, multibiomarker disease activity; MTX, methotrexate; NS, not significant; SHS, Sharp/van der Heijde score; TNF, tumour necrosis factor. Karen Hambardzumyan et al. RMD Open 2016;2:e000197 Copyright © BMJ Publishing Group & EULAR. All rights reserved.